ArticleScientific reports2011
Enhancing apoptosis in TRAIL-resistant cancer cells using fundamental response rules.
Article in Scientific reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Network biology to artificial intelligence: building the next generation of predictive drug discovery.Frontiers in immunology · 2026Review
- Systems biology approach for enhancing limonene yield by re-engineering Escherichia coli.NPJ systems biology and applications · 2024Article
- Advancing drug-response prediction using multi-modal and -omics machine learning integration (MOMLIN): a case study on breast cancer clinical data.Briefings in bioinformatics · 2024Article
- Towards multi-omics synthetic data integration.Briefings in bioinformatics · 2024Review
- Systems Biology to Understand and Regulate Human Retroviral Proinflammatory Response.Frontiers in immunology · 2021Review
- The MUDENG Augmentation: A Genesis in Anti-Cancer Therapy?International journal of molecular sciences · 2020Review
- TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosis.Life science alliance · 2019Article
- Defining rules for cancer cell proliferation in TRAIL stimulation.NPJ systems biology and applications · 2019Article
- The apoptotic mechanisms of MT-6, a mitotic arrest inducer, in human ovarian cancer cells.Scientific reports · 2017Article
- Can the second law of thermodynamics hold in cell cultures?Frontiers in genetics · 2015Article
- Systems biology of death receptor networks: live and let die.Cell death & disease · 2014Review
- Systems Biology Strategy Reveals PKCδ is Key for Sensitizing TRAIL-Resistant Human Fibrosarcoma.Frontiers in immunology · 2014Article
- Parameter-less approaches for interpreting dynamic cellular response.Journal of biological engineering · 2014Article
- A systems biology approach to suppress TNF-induced proinflammatory gene expressions.Cell communication and signaling : CCS · 2013Article
- TRAIL on trial: preclinical advances in cancer therapy.Trends in molecular medicine · 2013Review
- Adenovirus-mediated combined anti-angiogenic and pro-apoptotic gene therapy enhances antitumor efficacy in hepatocellular carcinoma.Oncology letters · 2013Article
- Rab25 Small GTPase Mediates Secretion of Tumor Necrosis Factor Receptor Superfamily Member 11b (osteoprotegerin) Protecting Cancer Cells from Effects of TRAIL.Journal of genetic syndromes & gene therapy · 2013Article
- Is central dogma a global property of cellular information flow?Frontiers in physiology · 2012Article
- Mathematical and statistical modeling in cancer systems biology.Frontiers in physiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induces apoptosis in malignant cells, while leaving other cells mostly unharmed. However, several carcinomas remain resistant to TRAIL. To investigate the resistance mechanisms in TRAIL-stimulated human fibrosarcoma (HT1080) cells, we developed a computational model to analyze the temporal activation profiles of cell survival (IκB, JNK, p38) and apoptotic (caspase-8 and -3) molecules in wildtype and several (FADD, RIP1, TRAF2 and caspase-8) knock-down conditions. Based on perturbation-response approach utilizing the law of information (signaling flux) conservation, we derived response rules for population-level average cell response. From this approach, i) a FADD-independent pathway to activate p38 and JNK, ii) a crosstalk between RIP1 and p38, and iii) a crosstalk between p62 and JNK are predicted. Notably, subsequent simulations suggest that targeting a novel molecule at p62/sequestosome-1 junction will optimize apoptosis through signaling flux redistribution. This study offers a valuable prospective to sensitive TRAIL-based therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.